期刊文献+

抗CD20单克隆抗体在风湿性疾病治疗中的应用

下载PDF
导出
摘要 随着对B细胞在风湿性疾病发病机制中作用的进一步认识,相应的生物靶向治疗应运而生。研究表明,抗CD20单克隆抗体(Rituximab),可有效治疗包括类风湿关节炎、系统性红斑狼疮、中性粒细胞胞浆抗体(ANCA)相关系统性血管炎、皮肌炎、冷球蛋白血症、慢性冷凝集素病、多发性硬化等多种难治性自身免疫性疾病。现就B淋巴细胞在风湿性疾病中的发病机制。Rituximab治疗风湿性疾病的疗效和安全性方面的研究进展综述如下。
出处 《北京医学》 CAS 2008年第2期114-116,共3页 Beijing Medical Journal
  • 相关文献

参考文献24

  • 1Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am, 2004, 30:393 - 403.
  • 2Pitashny M, Shoenfeld Y. B cell depletion in autoimmune rheumatic diseases. Autoimmun Rev, 2005, 4:436 - 441.
  • 3Perosa F, Favoino E, Caragnano MA, et al. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev, 2005, 4:526 - 531.
  • 4Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs, 2002, 2:3 - 10.
  • 5Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid arthritis synovium is B cell dependent. J Immunology, 2001, 167:4710 - 4718.
  • 6李鸿斌,张奉春.B淋巴细胞克隆清除治疗类风湿关节炎的研究进展[J].中华医学杂志,2005,85(42):3021-3024. 被引量:4
  • 7Brodszky V, Czirjak L, Geher P, et al. Rituximab in patients with rheumatoid arthritis: systematic review. Orv Hetil, 2007, 148: 1883 - 1893.
  • 8Popa C, Leandro M J, Cambfidge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford), 2007, 46:626 - 630.
  • 9Edwards JC, Cambridge G. The use of Rituximab in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology, 2001, 40:205 - 211.
  • 10Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B - cell - targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004, 350:2572 - 2581.

二级参考文献29

  • 1Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 2001,40:205-211.
  • 2De Vita S, Zaja F,Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum,2002, 46:2029-2033.
  • 3Leandro MJ, Edwards JCW, Cambridge G.Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis,2002,61:883-888.
  • 4Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med,2004,17,350:2572-2581.
  • 5Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.Arthritis Res Ther, 2003,5:S12-16.
  • 6Cambridge G, Leandro MJ, Edwards JC,et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum, 2003,48:2146-2154.
  • 7Szczepan′ ski L, Szechin′ ski J, Filipowicz-Sosnowska A,et al.Infusions of rituximab in patients with rheumatoid arthritis are well tolerated. Ann Rheum Dis, 2003, (Suppl 1):171.
  • 8Moore J, Ma D, Will R,et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant,2004,34:241-247.
  • 9Bridges SL. Update on autoantibodies in rheumatoid arthritis.Curr Rheumatol Rep,2004,6:343-350.
  • 10Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum,1988,31:99-107.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部